Rules-Based Medicine

RBM, which held around $3 million in cash and cash equivalents as of the end of September, is developing a psychiatric diagnostics panel.

While RBM and Psynova wouldn't reveal for which drug or drugs they were developing a companion diagnostic, there is an investigational schizophrenia agent in Roche's pipeline, RG 1678, which improved negative symptoms of patients with the disease in a Phase II proof-of-concept study. Separately, RBM and Psynova have also released data on a panel of central nervous system biomarkers they plan to develop into a homebrew diagnostic test for schizophrenia.

RBM's Psynova Neurotech subsidiary will collaborate with Roche on developing companion diagnostics for schizophrenia treatments.

RBM will serve as the drug maker's provider of multiplexed biomarker testing services.

The firms are developing a test to differentiate schizophrenia from other psychiatric disorders.

According to Satoris, the 189-marker panel covers the "most physiologically relevant pathways and includes biomarkers known to be important in the major disease processes for drug development … [and] and thus provide researchers with critical biological information plus leads for further study."

The privately held molecular diagnostics firm will distribute RBM's pnale of biomarkers, which complements its own recently launched panels for neurological conditions.

People In The News

Compugen Named co-CEOs this week, while Rules-Based Medicine hired a new VP of clinical diagnostics, and an Affymetrix director decided to step down.

The partners are deciding whether to run the multiplex test on a microarray or a sequencing platform. Factors in the decision include the complexity of the test and the technical feasibility of multiplexed, targeted resequencing.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.